AEMD - Aethlon Med Inc. - Page 31

stock is down a little

Yea I think people are slowly selling their shares because this stock doesn't have anything going on. The potential with this stock is huge, imo, so I'm still holding. I keep buying shares when it gets really low.

good point adam, AEMD has HUGE potential, we gotta wait for the right PR to come out for it to go crazy.

everyone is in STTK, I think Aemd will get a run soon in the near future.

AEMD Files 8-K April 4, 2006. Check out their latest 8-K. For the full 8-K check the latest filing download at http://phx.corporate-ir.net/phoenix....588&p=irol-sec


Here's basically what happened:

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On March 31, 2006, Fusion Capital Fund II, LLC ("Fusion") exercised a warrant
(the "Warrant") to purchase 568,181 shares of the Company's common stock (the
"Shares") for $0.76 per share whereby the Company received $431,817.56. The
Shares are registered to an effective registration statement on Form SB-2. The
Company's Board of Directors approved the issuance of a warrant to purchase
568,181 shares of the Company's common stock (the "Replacement Warrant") as an
inducement for Fusion to exercise the Warrant with a cash payment. The five-year
Replacement Warrant, filed with this report as an exhibit, has an exercise price
of $0.76 per share and carries piggy-back registration rights. .
*************************************************

Not really sure what the ramifications are but wouldn't that give us good support base at $0.76 ? These guys aren'y gonna sell off for less. They should sell for higher, is there something in the works for a jump or was AEMD just raising capital ? For sure some big money was invested and that gives me confidence in the stock. GLTA

That sounds to me like they are planning for something big!

I don't chat a lot by these time but guys, I'm keeping this one !

News!!!!!

SAN DIEGO--(BUSINESS WIRE)--April 5, 2006--Aethlon Medical, Inc.
(OTCBB:AEMD), a pioneer in developing therapeutic devices for
infectious disease, announced today that its Chairman and CEO, James
A. Joyce has been named to the Biodefense Priorities, Programs, and
Funding Panel at the 2006 Homeland and Global Security Summit. The
Summit is being held on April 11 at the Washington Convention Center
in Washington, D.C. The other panel members are:


-- Steven Perkins, Vice President, Business Development and
Strategy, Northrop Grumman Corporation.

-- Dr. Charles R. Gallaway, Director, Chemical-Biological Defense
Directorate, Defense Threat Regulatory Agency (DTRA).

-- Major General Bruce E. Davis, Commander, Joint Task Force
Civil Support, US Northern Command.

Additional details on the 2006 Homeland and Global Security Summit
can be accessed at
http://www.globalsecurity.bz/confere...gss/2006/index.
asp.

Thats really good news. AEMD has been trying to get funding... now their CEO is on the Funding Panel! I'm really looking forward to seeing what happens on April 11th.

Up to .82 so far!

adamfrdmn1 "I'm really looking forward to seeing what happens on April 11th."

What happens April 11th?

"announced today that its Chairman and CEO, James A. Joyce has been named to the Biodefense Priorities, Programs, and Funding Panel at the 2006 Homeland and Global Security Summit. The Summit is being held on April 11 at the Washington Convention Center in Washington, D.C."

Hopefully they can get some sort of funding, need some PR for this stock, I bought in @ .33 and still holding strong.

More news today. Volume is up, although the price is down.

-------------------
Aethlon Medical Submits for NIH Cancer Research Grant


By BusinessWire
Last Update: 4/11/2006 9:34:19 AM Data provided by

SAN DIEGO, Apr 11, 2006 (BUSINESS WIRE) -- Aethlon Medical, Inc. (AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that it has submitted a cancer research grant application entitled "Tumor Exosome Removal to Stimulate Cancer-Specific Immunity." The grant was submitted to the National Institute of Health (NIH) and directed to the National Cancer Institute as a Phase I Small Business Innovation Grant. A review and formal response to the grant application is expected from the NIH in August. The grant application discusses the potential use of the Aethlon Hemopurifier(TM )as a method to remove exosomes that suppress the immune response in cancer patients. Significant levels of immune-suppressive exosomes are identified in cancer patients, whereas healthy individuals maintain negligible levels. Aethlon proposes to improve the immune response to malignancies by reducing the presence of tumor-derived exosomes, thereby activating immunity to cancers. There is no assurance that Aethlon will derive grant income related to this research initiative.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

SOURCE: Aethlon Medical, Inc.

News today !!!!


SAN DIEGO--(BUSINESS WIRE)--April 12, 2006--Aethlon Medical, Inc.
(OTCBB:AEMD), a pioneer in developing therapeutic devices for
infectious disease, announced today that it has submitted an Avian
Flu-related grant application entitled, "Extracorporeal Treatment of
H5N1 Bird Flu Viral Sepsis." The grant was submitted to the National
Institutes of Health (NIH) to be directed to the National Institute of
Allergy and Infectious Disease (NIAID) as a Phase I Small Business
Innovation Grant. The grant application discusses the deployment of
the Aethlon Hemopurifier(TM) as a therapy to clear inflammatory
cytokines, H5N1 Avian Flu virus and viral fragments that stimulate
viral sepsis. Grant collaborators include Dr. Leo L.M. Poon, Assistant
Professor at the University of Hong Kong, Department of Microbiology,
and Dr. Kevin Gilligan, Senior Scientist at Commonwealth
Biotechnologies. There is no assurance that Aethlon will derive grant
income related to this research initiative.

Seems to be another boring day in terms of the stock price and volume...

Atleast AEMD is obviously making steps towards their goals though, as seen with their recent PR's.

Anyone know whats going on? Are the MM's trying to lower the price? It's getting to the point where I'm nearly breaking even...

AEMD completes first human trials in India

Wednesday, April 19 2006 10:07 AM, EST

--------------------------------------------------------------------------------

Aethlon Medical Completes Human Safety Study
Business Editors

SAN DIEGO--(BUSINESS WIRE)--April 19, 2006-- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that a safety study of patients treated with the Aethlon Hemopurifier(TM) has been successfully completed at the Apollo Hospital in Delhi, India. Aethlon will include data from the study in Pandemic Influenza and Class "A" Biological Weapon regulatory filings to be submitted to the Food and Drug Administration (FDA). The demonstration of safety represents the sole human challenge for therapeutic candidates seeking clearance to treat these indications in the United States. Dr. Vijay Kher, the principal investigator of the safety study, now plans to initiate human efficacy studies of the Hemopurifier(TM) as a treatment for chronic and acute viral conditions in India. Aethlon management is currently working with Dr. Kher, advisors at Qualtran, LLC, and government officials in India to determine the infectious disease target of the initial efficacy study.

A Review of the Safety Study

Aethlon demonstrated treatment safety of the Hemopurifier(TM) in all patients enrolled in the study. Each patient suffered from end-stage renal disease (requiring kidney dialysis treatment) as well as Hepatitis-C (HCV) infection. A total of four patients met the conditions to be enrolled and were treated in the study. The average patient age exceeded 50 years, and as a result of their severe condition, spent greater than 50% of their waking hours in bed. The treatment regimen required each patient to be treated six times with the Hemopurifier over a two-week time frame. Each treatment lasted four hours. The treatment regimen mirrored the patient's normal kidney dialysis schedule, which allowed for the inclusion of the Hemopurifier(TM) without disrupting dialysis treatment. Blood chemistry and general health of the patients were monitored throughout the study, and at the conclusion of the study, no material adverse events had been observed. In addition to demonstrating safety, Aethlon researchers observed an approximate 30% capture of circulating HCV during each examined four-hour treatment. Blood samples from the first and last treatment sessions were sent to independent labs to seek further validation. These results were deemed uninterruptible as the same blood samples yielded up to a four-fold variance in viral load measurements from the two participant labs. "The completion of our first human study represents our most significant milestone to date," stated Aethlon Chairman and CEO, James A. Joyce. "The recruitment of patients meeting the criteria of being afflicted with both kidney failure and Hepatitis-C did cause significant delay." "However, the demonstration of safety in individuals with such severely compromised health conditions will be considerably more valuable to our efforts moving forward," concluded Joyce.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at http://www.aethlonmedical.com.

Wow that great news , imagine what we've got here with FDA approval!

ended today at .73... I knew it wouldn't stay at that low price of 60 cents for long

Anyone know why this is going down?